Obesity

GLP-1 receptor agonists are increasingly being used to treat obesity in adolescents.

Kay Rhee, MD, discusses the challenges of pediatric obesity treatment, highlighting the role of biological and environmental factors, behavioral interventions, and the potential benefits of GLP-1 medications in weight management for children and teens.

In her September 2024 article, Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights the potential of digital health tools to improve care for pediatric mental health, obesity, and medically complex conditions.

Investigators found the association for higher BMI, increased obesity risk, and increased severe obesity risk.

Following the FDA's acceptance of the NDA, a PDUFA date of December 26, 2024 has been set for setmelanotide in patients as young as 2 years of age.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Digital tools like health apps, texts, and telemedicine show promise in managing childhood obesity, but require sustained engagement for long-term impact.

A recent study reveals a direct association between higher maternal body mass index and the risk of sudden unexpected infant death, underscoring the need for further research into the causal mechanisms.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the July 2024 issue of Contemporary Pediatrics.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Wondering what’s the best way to talk to children about their weight? Colleen Sloan, PA-C, RDN, provides some clinical pearls you can incorporate into your practice.

Participants included adolescents aged 13 to 17 years with severe obesity, defined as at or greater than 120% of the 95th BMI percentile.

The USPSTF is encouraging providers to promote behavioral interventions as the primary effective intervention for weight loss in children and adolescents.

A recent study suggests that high ultraprocessed food consumption in preschool children is linked to increased cardiometabolic risk factors.

Drugs like semaglutide and liraglutide were dispensed at unprecedented increased rates for adolescents and young adults over a span of just 4 years.

Investigators found that higher baseline HbA1c was associated with greater T2D risk.

Even 6 years after publication, the investigative team stated it is unknown if the recommendations have led to changes in primary care.

Across all age groups, obesity rates increased during the pandemic and decreased in the post-pandemic period (P < 0.01).

A poster session evaluated early evidence from the randomized controlled iREACH trial.

TNX-2900 was previously granted Orphan Drug designation by the federal agency in 2022 for the treatment of PWS.

Though the association of BMI gain and 100% fruit juice in children was “small,” authors concluded their findings support public health guidance to limit consumption of the beverage to prevent overweight and obesity.

The United States Preventive Services Task Force (USPSTF) is planning to recommend that comprehensive, intensive behavioral interventions be the primary effective intervention for weight loss in children and adolescents with high body mass indexes (BMI).

In a systematic and meta-analysis review of cohort studies that featured nearly 1.7 million individuals, study authors concluded that there is an association between high body mass index (BMI) and an increased risk of incident type 1 diabetes (T1D).

Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.

To combat this association, study investigators concluded a reduction in daily soft drink consumption should be a priority among school-going adolescents.